Status:

COMPLETED

Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961)

Lead Sponsor:

Merck Sharp & Dohme LLC

Conditions:

Anesthesia

Eligibility:

All Genders

28-65 years

Phase:

PHASE3

Brief Summary

The purpose of this study is: * to explore the dose-response relation of sugammadex (Org 25969, MK-8616, SCH 900616) given as a reversal agent at reappearance of T2 after 0.6 mg.kg-1 rocuronium in pe...

Eligibility Criteria

Inclusion

  • American Society of Anesthesiologists (ASA) class 1 - 2, between the ages of 28 days and 65 years inclusive, and between the ages of 2 and 65 years inclusive for Germany and between the ages of 6 and 65 years inclusive for Finland
  • Scheduled for general anesthesia with an anticipated duration of anesthesia of at least 60 minutes, without further need for muscle relaxation other than one single dose of 0.6 mg/kg rocuronium
  • Scheduled for surgical procedures in the supine position
  • Participants who, and/or whose parent(s) or legal guardian(s) have given written informed consent \[or appropriate assent, if applicable\]

Exclusion

  • Known or suspected neuromuscular disorders impairing neuromuscular blockade (NMB) and/or significant renal dysfunction, in Germany creatinine and blood urea nitrogen outside local reference ranges
  • Known or suspected to have a (family) history of malignant hyperthermia
  • Known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia
  • Use of medication expected to interfere with the rocuronium given in this trial, based on the dose and the time of administration
  • Pregnancy
  • Childbearing potential not using any of the following methods of birth control: condom or diaphragm with spermicide, vasectomized partner (\>6 months), intrauterine device (IUD), abstinence
  • Breast-feeding
  • Prior participation in any study with Org 25969 (sugammadex)
  • Participation in another clinical trial, not pre-approved by NV Organon, within 30 days of entering into study 19.4.306 (MK-8616-034, P05961)

Key Trial Info

Start Date :

May 30 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 2 2006

Estimated Enrollment :

94 Patients enrolled

Trial Details

Trial ID

NCT00421148

Start Date

May 30 2005

End Date

June 2 2006

Last Update

January 28 2019

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.